Eloxx Pharmaceuticals announced that CEO Sumit Aggarwal will present at the 3rd Annual Guggenheim Healthcare Innovation Conference on November 9, 2026. The company is developing exaluren, a treatment for rare kidney diseases caused by nonsense mutations, including Alport syndrome and ADPKD. The presentation will be webcast live and available for replay, highlighting Eloxx's progress in clinical-stage biopharmaceutical development. This event offers investors insight into Eloxx's innovative approach to treating rare genetic conditions.
Eloxx Pharmaceuticals' upcoming presentation at the Guggenheim Healthcare Innovation Conference is contextually framed by Pluang's health sector data. As of Nov 03, 2026 04:11 WIB, 48 out of 150 health stocks rose while 100 fell. Notable movers include AMWL at USD 12.71 with a -15.15% change, REGN at USD 927.38 up 13.27%, and DNA at USD 9.81 down 12.60%.
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
Exosens disclosed its monthly update on the total number of shares and voting rights in its share capital as of October 31, 2026. The company has 50,936,749 shares outstanding, with 59,162,039 exercisable voting rights after deducting treasury shares...
Exosens has released its monthly update on the total number of shares and voting rights composing its capital as of October 31, 2026. The company reports 50,936,749 total shares and 59,425,768 theoretical voting rights, with 59,162,039 exercisable vo...
Recursion Pharmaceuticals announced positive Phase 2 results for REC-4881, an oral MEK1/2 inhibitor, in treating familial adenomatous polyposis (FAP). The TUPELO trial showed a 47% median reduction in total polyp burden after 12 weeks of treatment, w...
Vornado Realty Trust reported a net loss of $47.1 million for Q3 2026, a decline from net income of $11.6 million in the prior year period, primarily due to a large gain in 2025 related to a master lease. However, funds from operations (FFO) increase...
